Details of the Drug Combination

General Information of Drug Combination (ID: DCJPYCN)

Drug Combination Name
Cabazitaxel ABIRATERONE
Indication
Disease Entry Status REF
Clear cell renal cell carcinoma Investigative [1]
Component Drugs Cabazitaxel   DMPAZHC ABIRATERONE   DM8V75C
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: 786-0
Zero Interaction Potency (ZIP) Score: 2
Bliss Independence Score: 3.17
Loewe Additivity Score: 0.98
LHighest Single Agent (HSA) Score: 4.9

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Cabazitaxel
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Metastatic prostate carcinoma N.A. Investigative [3]
Cabazitaxel Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Inhibitor [5]
------------------------------------------------------------------------------------
Cabazitaxel Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [6]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [6]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Cabazitaxel Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Forkhead box protein O3 (FOXO3) OTHXQG4P FOXO3_HUMAN Affects Expression [7]
Proline-rich AKT1 substrate 1 (AKT1S1) OT4JHN4Y AKTS1_HUMAN Decreases Expression [7]
------------------------------------------------------------------------------------
Indication(s) of ABIRATERONE
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [4]
ABIRATERONE Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Steroid 17-alpha-monooxygenase (S17AH) TTRA5BZ CP17A_HUMAN Modulator [8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCYIDLH NCIH23 Investigative [1]
Adenocarcinoma DCCB8NU SW-620 Investigative [1]
Adenocarcinoma DCZXGLB HCT-15 Investigative [1]
Adenocarcinoma DCT200A HCC-2998 Investigative [1]
Amelanotic melanoma DCXPVJO MDA-MB-435 Investigative [1]
Amelanotic melanoma DCAZSGX M14 Investigative [1]
Astrocytoma DCXQMN5 U251 Investigative [1]
Childhood T acute lymphoblastic leukemia DCDZAKB CCRF-CEM Investigative [1]
Chronic myelogenous leukemia DC6ZX9I K-562 Investigative [1]
Clear cell renal cell carcinoma DCCI7CX TK-10 Investigative [1]
Cutaneous melanoma DC4RJLS SK-MEL-28 Investigative [1]
Glioma DCI3O6Z SF-539 Investigative [1]
Glioma DCPLFKR SF-268 Investigative [1]
High grade ovarian serous adenocarcinoma DCFEPRS NCI\\/ADR-RES Investigative [1]
Lung adenocarcinoma DCH95OO HOP-62 Investigative [1]
Malignant melanoma DCDP000 LOX IMVI Investigative [1]
Melanoma DCMEVCL UACC-257 Investigative [1]
Melanoma DCPYRRY MALME-3M Investigative [1]
Mixed endometrioid and clear cell carcinoma DCC013U IGROV1 Investigative [1]
Pleural epithelioid mesothelioma DCDXLIA NCI-H226 Investigative [1]
Breast adenocarcinoma DCA3ZES MDA-MB-468 Investigative [9]
Carcinoma DCN7AIM MCF7 Investigative [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 22 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6798).
3 Cabazitaxel FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6745).
5 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
6 DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
7 The triphenyltin carboxylate derivative triphenylstannyl 2-(benzylcarbamoyl)benzoate impedes prostate cancer progression via modulation of Akt/FOXO3a signaling. Toxicol Appl Pharmacol. 2020 Aug 15;401:115091. doi: 10.1016/j.taap.2020.115091. Epub 2020 Jun 7.
8 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
9 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165